Posted by Michael Wonder on 07 Dec 2021
BeiGene announces inclusion in the China National Reimbursement Drug List (NRDL) of tislelizumab in three new indications, Brukinsa (zanubrutinib) in one new indication, and the first listing for pamiparib
2 December 2021 - BeiGene today announced that three of its medicines have been added to the most recent National Reimbursement Drug List in China by the National Healthcare Security Administration.
BeiGene discovered medicines in the updated National Reimbursement Drug List include: anti-PD-1 antibody tislelizumab in three new indications, including in lung and liver cancers; the BTK inhibitor Brukinsa (zanubrutinib) in one new indication; and the initial listing for PARP inhibitor pamiparib.
The changes to the NRDL will be effective on 1 January 2022.
